Search 

A private company based in Scotland, MGB Biopharma is a clinical stage Biopharma developing a novel class of antibiotics with a novel mechanism of action to treat drug-resistant bacteria. MGB has developed two strongly bactericidal formulations of its lead compound MGB-BP-3:

• An oral formulation for treating Clostridium difficile infections that has shown superiority over vancomycin, including the hyper virulent strain NAP1-027, and

• An i.v. formulation for treating systemic AMR Gram-positive hospital-acquired infections with promising in vivo efficacy data in MRSA and Streptococcus. In addition, the Company has a programme to investigate a topical formulation of its lead compound and to explore the activity of other compounds in the MGB platform against Gram-negative pathogens.